Caricamento...
Interferon-β exacerbates Th17 inflammatory diseases
Interferon-β (IFN-β) is the treatment most often prescribed for relapsing-remitting multiple sclerosis (RRMS). However, 30–50% of MS patients do not respond to IFN-β. In some cases, IFN-β exacerbates MS, and it consistently worsens neuromyelitis optica (NMO). In order to eliminate unnecessary treatm...
Salvato in:
| Pubblicato in: | Trends Immunol |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2011
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5414634/ https://ncbi.nlm.nih.gov/pubmed/21530402 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.it.2011.03.008 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|